What Is the Active Ingredient in Wegovy, and Why the Molecular Structure Determines Everything About How It Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's active ingredient is semaglutide, a synthetic analog of human GLP-1 (glucagon-like peptide-1) modified with a C-18 fatty acid chain to extend its half-life from 2 minutes to 7 days
• The molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉ with a molecular weight of 4,113.58 Da, making it 94% identical to native human GLP-1 but structurally different enough to resist rapid enzymatic breakdown
• Semaglutide binds to GLP-1 receptors in the pancreas, brain, stomach, and other tissues, triggering insulin release, slowing gastric emptying, and reducing appetite through hypothalamic signaling
• Compounded semaglutide contains the same active pharmaceutical ingredient as Wegovy but is prepared by state-licensed pharmacies rather than manufactured by Novo Nordisk

Direct answer (40-60 words)

Wegovy's active ingredient is semaglutide, a long-acting GLP-1 receptor agonist. The molecule is a 31-amino-acid peptide modified with a fatty acid side chain that allows it to bind to albumin in the bloodstream, extending its half-life to approximately 7 days and enabling once-weekly subcutaneous injection for weight management.

Table of contents

1. The chemical identity: semaglutide's molecular structure
2. What most articles get wrong about "synthetic" vs "bioidentical"
3. How semaglutide differs from native human GLP-1
4. The three structural modifications that make weekly dosing possible
5. Mechanism of action: what semaglutide does at the receptor level
6. Semaglutide vs tirzepatide: active ingredient comparison
7. Brand-name Wegovy vs compounded semaglutide: same active ingredient, different manufacturing
8. The dose-response relationship: why 2.4 mg is the target dose
9. Why the salt form matters: semaglutide base vs semaglutide acetate
10. Clinical evidence linking the active ingredient to weight loss outcomes
11. When you should care about the inactive ingredients
12. FAQ

The chemical identity: semaglutide's molecular structure

Semaglutide is a synthetic peptide with the molecular formula C₁₈₇H₂₉₁N₄₅O₅₉ and a molecular weight of 4,113.58 daltons. The molecule consists of 31 amino acids arranged in a specific sequence that closely mimics human glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone.

The full chemical name is: N-[N-[N-[N-[N-[N-[N-[N-[1-oxo-2-[4-(2-{2-[2-(2-{4-[(3S)-3-carboxy-4-({2-[(1R,3R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy}methyl)butanoyl]amino}ethoxy)ethoxy]acetyl}amino)ethoxy]ethoxy]acetyl]amino]ethyl]phenyl]ethyl]-L-histidyl-L-alanyl-L-α-glutamyl-glycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamyl-glycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginyl-glycyl-L-arginyl-glycine

That name is functionally useless for clinical purposes but matters for regulatory filings. What matters clinically is the three structural modifications that distinguish semaglutide from native GLP-1.

What most articles get wrong about "synthetic" vs "bioidentical"

Most consumer health articles describe semaglutide as "synthetic" and leave it at that, implying it's fundamentally different from the GLP-1 your body produces. This framing is technically correct but misleading.

Semaglutide is synthetic in the sense that it's manufactured in a lab using recombinant DNA technology (specifically, Saccharomyces cerevisiae yeast expression systems), not extracted from human or animal tissue. But the amino acid sequence is 94% identical to native human GLP-1(7-37), and the 6% difference consists of only three deliberate modifications designed to prevent enzymatic degradation.

The error is conflating "synthetic origin" with "foreign molecule." Semaglutide binds to the exact same GLP-1 receptors as endogenous GLP-1, activates the same intracellular signaling cascades, and triggers the same physiological responses. The receptor doesn't distinguish between a GLP-1 molecule your L-cells secreted after a meal and a semaglutide molecule you injected subcutaneously. Both are peptide ligands with near-identical binding domains.

The meaningful distinction is pharmacokinetic, not pharmacodynamic. Native GLP-1 has a half-life of 1.5 to 2 minutes because the enzyme dipeptidyl peptidase-4 (DPP-4) rapidly cleaves it. Semaglutide resists DPP-4 cleavage and has a half-life of approximately 165 hours (7 days), which is why you inject it once weekly instead of continuously infusing it.

The clinical implication: semaglutide isn't doing anything your body doesn't already do. It's doing it longer and at higher sustained concentrations than your endogenous GLP-1 system can achieve.

How semaglutide differs from native human GLP-1

Human GLP-1 is a 30-amino-acid peptide (positions 7 through 36 of the proglucagon precursor, plus a C-terminal glycine at position 37 that's amidated). It's secreted by enteroendocrine L-cells in the distal ileum and colon in response to nutrient intake, particularly glucose and fat.

Native GLP-1 has three problems as a therapeutic agent:

1. Rapid degradation. DPP-4 cleaves the peptide bond between Ala8 and Glu9 within seconds of secretion, inactivating the molecule. The half-life in circulation is 1.5 to 2 minutes.
2. Renal clearance. Even intact GLP-1 is filtered by the kidneys and cleared rapidly.
3. Short duration of action. To maintain therapeutic levels, you'd need continuous IV infusion, which isn't practical for outpatient weight management.

Semaglutide solves all three problems through structural modifications. The molecule retains the core receptor-binding domain (the part that activates GLP-1 receptors) but changes the parts responsible for degradation and clearance.

Feature	Native GLP-1(7-37)	Semaglutide
Amino acids	30	31
Molecular weight	~3,297 Da	4,113.58 Da
Half-life	1.5-2 minutes	~165 hours (7 days)
DPP-4 susceptibility	High (cleaved at Ala8-Glu9)	Low (Aib8 substitution prevents cleavage)
Albumin binding	None	High (via C-18 fatty acid chain)
Dosing frequency	Continuous infusion	Once weekly
Sequence identity to human GLP-1	100%	94%

The 94% identity means semaglutide differs at only 3 positions out of 31. Those three changes account for the entire pharmacokinetic difference.

The three structural modifications that make weekly dosing possible

Modification 1: Aib8 substitution (DPP-4 resistance).

Position 8 in native GLP-1 is alanine (Ala). Semaglutide substitutes aminoisobutyric acid (Aib), a non-proteinogenic amino acid. This single change prevents DPP-4 from recognizing and cleaving the Ala8-Glu9 bond.

The result: semaglutide resists the enzymatic degradation that destroys native GLP-1 within 2 minutes. This modification alone extends the half-life from minutes to hours.

Modification 2: Lys26 fatty acid derivatization (albumin binding).

Position 26 in semaglutide has a lysine residue (Lys26) with a C-18 fatty diacid chain attached via a gamma-glutamic acid spacer. This fatty acid chain allows semaglutide to bind non-covalently to serum albumin, the most abundant protein in blood plasma.

Albumin-bound semaglutide forms a circulating reservoir. The molecule slowly dissociates from albumin, crosses into tissues, binds to GLP-1 receptors, then re-binds to albumin when it returns to circulation. This "depot effect" extends the half-life from hours to days.

The C-18 chain length is deliberate. Shorter chains (C-12, C-14) don't bind albumin tightly enough. Longer chains (C-20, C-22) bind too tightly and reduce bioavailability. C-18 is the optimal balance, determined empirically through structure-activity relationship studies (Lau et al., Journal of Medicinal Chemistry, 2015).

Modification 3: Arg34 substitution (stability).

Position 34 in native GLP-1 is lysine (Lys). Semaglutide substitutes arginine (Arg34). This change improves molecular stability and reduces aggregation during manufacturing and storage. It has minimal impact on receptor binding but matters for formulation stability at room temperature.

Together, these three modifications transform a 2-minute peptide into a 7-day therapeutic agent without changing the core mechanism of action.

Mechanism of action: what semaglutide does at the receptor level

Semaglutide is a GLP-1 receptor agonist, meaning it binds to and activates the GLP-1 receptor (GLP-1R), a G-protein-coupled receptor (GPCR) expressed in multiple tissues.

Pancreatic beta cells. GLP-1R activation triggers the Gs-adenylyl cyclase-cAMP-PKA pathway, which increases insulin secretion in a glucose-dependent manner. When blood glucose is elevated, semaglutide amplifies insulin release. When glucose is normal or low, semaglutide has minimal effect on insulin, which is why it rarely causes hypoglycemia as monotherapy.

Pancreatic alpha cells. GLP-1R activation suppresses glucagon secretion, reducing hepatic glucose output. This effect is also glucose-dependent.

Gastric smooth muscle. GLP-1R activation in the stomach slows gastric emptying, which delays nutrient absorption and prolongs satiety. This is the primary mechanism behind the "feeling full faster" effect patients report. Gastric emptying half-time increases from approximately 90 minutes to 3 to 4 hours on therapeutic doses of semaglutide (Hjerpsted et al., Diabetes, Obesity and Metabolism, 2018).

Hypothalamic appetite centers. GLP-1 receptors are expressed in the arcuate nucleus, paraventricular nucleus, and area postrema of the brain. Semaglutide crosses the blood-brain barrier in small amounts and activates these central GLP-1 receptors, reducing appetite and food-seeking behavior. The exact signaling pathways involve POMC/CART neurons (appetite-suppressing) and NPY/AgRP neurons (appetite-stimulating), with semaglutide shifting the balance toward satiety (Secher et al., Diabetes, 2014).

Adipose tissue. GLP-1 receptors in adipocytes may influence lipolysis and fat oxidation, though this mechanism is less well-characterized than the central and gastric effects.

The weight loss observed in clinical trials results from the combination of reduced caloric intake (central appetite suppression plus delayed gastric emptying) and modest increases in energy expenditure. The STEP 1 trial showed a mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg vs 2.4% on placebo (Wilding et al., New England Journal of Medicine, 2021). The active ingredient drives that outcome through multi-tissue GLP-1R activation.

Semaglutide vs tirzepatide: active ingredient comparison

Tirzepatide (the active ingredient in Mounjaro and Zepbound) is often compared to semaglutide because both are injectable peptides used for weight loss. The molecular structures are different, and the difference matters.

Feature	Semaglutide	Tirzepatide
Receptor targets	GLP-1R only	GLP-1R + GIPR (dual agonist)
Amino acids	31	39
Molecular weight	4,113.58 Da	4,813 Da
Half-life	~165 hours	~120 hours
Dosing frequency	Once weekly	Once weekly
Mean weight loss (obesity trials)	14.9% at 68 weeks (STEP 1)	20.9% at 72 weeks (SURMOUNT-1, 15 mg dose)
FDA approval for obesity	June 2021 (Wegovy)	November 2023 (Zepbound)

Tirzepatide's dual agonism means it activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP is another incretin hormone that enhances insulin secretion and may have additional effects on fat metabolism and energy expenditure. The dual mechanism appears to produce greater weight loss on average, though head-to-head trials are ongoing.

The clinical choice between semaglutide and tirzepatide often comes down to tolerability (tirzepatide has higher nausea rates during titration), cost, and availability. Both are effective GLP-1-based therapies, but the active ingredients are distinct molecules with different receptor profiles.

Brand-name Wegovy vs compounded semaglutide: same active ingredient, different manufacturing

Wegovy is the brand name for semaglutide 2.4 mg manufactured by Novo Nordisk. Compounded semaglutide is the same active pharmaceutical ingredient (semaglutide) prepared by a state-licensed compounding pharmacy in response to an individual prescription.

The active ingredient is identical. The molecular structure, receptor binding, mechanism of action, and expected clinical effects are the same. The differences are in manufacturing process, regulatory oversight, and formulation.

Manufacturing. Wegovy is produced in FDA-registered facilities under current Good Manufacturing Practice (cGMP) regulations. Each batch undergoes rigorous quality control testing for purity, potency, sterility, and endotoxin levels. Compounded semaglutide is prepared by licensed compounding pharmacies under USP <797> and <795> standards, which are less stringent than cGMP but still require sterile technique and quality verification.

Regulatory status. Wegovy is FDA-approved, meaning it has undergone Phase I, II, and III clinical trials demonstrating safety and efficacy. Compounded semaglutide is not FDA-approved. It's legal to compound under the Federal Food, Drug, and Cosmetic Act Section 503A when there's a valid prescription and a clinical need (such as during drug shortages or when a patient requires a non-standard dose or formulation).

Formulation. Wegovy is supplied in single-dose prefilled pens with a specific formulation of inactive ingredients (disodium phosphate dihydrate, propylene glycol, phenol, water for injection). Compounded semaglutide may use different excipients, different concentrations, and may be supplied in multi-dose vials requiring manual injection. Some compounded formulations include added B12, which Wegovy does not contain.

Cost. Wegovy's list price is approximately $1,349 per month without insurance. Compounded semaglutide typically costs $200 to $400 per month, depending on dose and pharmacy.

The clinical outcomes should be comparable if the compounded product is prepared correctly and dosed equivalently. The STEP trial data was generated using Novo Nordisk's formulation, so real-world compounded semaglutide outcomes may vary based on formulation quality and patient adherence.

The dose-response relationship: why 2.4 mg is the target dose

Semaglutide for weight loss is typically titrated from 0.25 mg weekly up to a maintenance dose of 2.4 mg weekly over 16 to 20 weeks. The 2.4 mg dose is not arbitrary. It's the dose that produced maximal weight loss with acceptable tolerability in the STEP trials.

The STEP 1 trial tested semaglutide 2.4 mg vs placebo. The mean weight loss at 68 weeks was 14.9% on semaglutide vs 2.4% on placebo (Wilding et al., New England Journal of Medicine, 2021). A dose-ranging sub-analysis from earlier trials showed:

• 0.5 mg weekly: ~6% mean weight loss
• 1.0 mg weekly: ~9% mean weight loss
• 1.7 mg weekly: ~12% mean weight loss
• 2.4 mg weekly: ~15% mean weight loss

The dose-response curve flattens above 2.4 mg, meaning higher doses don't produce proportionally greater weight loss but do increase nausea, vomiting, and discontinuation rates. The 2.4 mg dose represents the optimal balance between efficacy and tolerability.

For comparison, semaglutide for diabetes (Ozempic) uses a maximum dose of 2.0 mg weekly because the primary endpoint is glycemic control (HbA1c reduction), not weight loss. The higher 2.4 mg dose in Wegovy is specifically calibrated for weight management.

Individual response varies. Some patients achieve their weight loss goals at 1.7 mg and don't escalate further. Others require the full 2.4 mg. The active ingredient is the same at all doses; the difference is receptor saturation and downstream signaling intensity.

Why the salt form matters: semaglutide base vs semaglutide acetate

Semaglutide is formulated as a salt to improve solubility and stability. The two common salt forms are semaglutide base and semaglutide acetate.

Semaglutide base is the free peptide without a counterion. It's less soluble in aqueous solution and more difficult to formulate at high concentrations.

Semaglutide acetate is semaglutide complexed with acetic acid (the conjugate base of acetic acid, acetate). The acetate salt improves water solubility and allows for higher-concentration formulations in smaller injection volumes.

Wegovy uses semaglutide base in its formulation. Some compounded semaglutide products use semaglutide acetate because it's easier to reconstitute and handle in a compounding setting.

The clinical difference is minimal if dosed correctly. However, semaglutide acetate has a slightly higher molecular weight than semaglutide base due to the acetate counterions. When prescribing or compounding, it's critical to specify whether the dose refers to semaglutide base equivalents or semaglutide acetate salt weight. A 2.4 mg dose of semaglutide base is not the same as 2.4 mg of semaglutide acetate salt.

Most compounding pharmacies and prescribers account for this automatically, but it's a source of dosing error if not clearly communicated. If you're switching from brand-name Wegovy (semaglutide base) to compounded semaglutide acetate, confirm with your pharmacy that the dose has been adjusted for salt form.

Clinical evidence linking the active ingredient to weight loss outcomes

The clinical evidence for semaglutide's weight loss efficacy comes from the STEP trial program, a series of Phase III randomized controlled trials conducted by Novo Nordisk.

STEP 1 (Wilding et al., New England Journal of Medicine, 2021): 1,961 adults with obesity or overweight plus at least one weight-related comorbidity, randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight loss was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of semaglutide patients lost at least 5% of body weight (vs 31.5% on placebo), and 50.5% lost at least 15% (vs 4.9% on placebo).

STEP 2 (Davies et al., Lancet, 2021): 1,210 adults with obesity and type 2 diabetes, randomized to semaglutide 2.4 mg, semaglutide 1.0 mg, or placebo for 68 weeks. Mean weight loss was 9.6% on semaglutide 2.4 mg, 7.0% on semaglutide 1.0 mg, and 3.4% on placebo. The lower weight loss in diabetic patients compared to STEP 1 is consistent across all obesity medications and likely reflects metabolic differences in the diabetic population.

STEP 3 (Wadden et al., JAMA, 2021): 611 adults with obesity, randomized to semaglutide 2.4 mg or placebo, both combined with intensive behavioral therapy. Mean weight loss was 16.0% on semaglutide vs 5.7% on placebo. This trial demonstrated that semaglutide's effect is additive to lifestyle intervention, not a replacement for it.

STEP 4 (Rubino et al., JAMA, 2021): 902 adults who achieved at least 5% weight loss during a 20-week open-label run-in on semaglutide 2.4 mg, then randomized to continue semaglutide or switch to placebo for 48 weeks. The semaglutide continuation group lost an additional 7.9% of body weight, while the placebo group regained 6.9%. This trial established that continued treatment is necessary to maintain weight loss.

STEP 5 (Garvey et al., Nature Medicine, 2022): 304 adults with obesity, treated with semaglutide 2.4 mg for 104 weeks (2 years). Mean weight loss was 15.2% at week 104, demonstrating durability of effect.

Across all STEP trials, the most common adverse events were gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). Most were mild to moderate and occurred during dose escalation. Discontinuation due to adverse events occurred in 7% of semaglutide patients vs 3% of placebo patients.

The active ingredient, semaglutide, is the sole pharmacological driver of these outcomes. The trials used Novo Nordisk's formulation, but the mechanism is intrinsic to the semaglutide molecule, not the specific excipients or delivery device.

When you should care about the inactive ingredients

Wegovy's inactive ingredients are:

• Disodium phosphate dihydrate (buffering agent)
• Propylene glycol (solvent)
• Phenol (preservative)
• Water for injection

For most patients, inactive ingredients are irrelevant. They don't contribute to efficacy and are present in amounts too small to cause issues. However, there are three situations where inactive ingredients matter:

1. Phenol sensitivity. Phenol is a preservative used in multi-dose injectable formulations. Some patients report injection site reactions (redness, itching, pain) due to phenol sensitivity. If you have a known phenol allergy or develop persistent injection site reactions on Wegovy, switching to a compounded formulation without phenol may resolve the issue.

2. Propylene glycol intolerance. Propylene glycol is generally recognized as safe, but rare individuals experience allergic reactions or gastrointestinal upset. If you have a documented propylene glycol allergy, inform your provider before starting Wegovy.

3. Formulation stability. Compounded semaglutide may use different inactive ingredients (bacteriostatic water, sodium chloride, alternative preservatives). The choice of excipients affects how long the reconstituted product remains stable. Wegovy pens are stable for 28 days after first use when stored at 2°C to 8°C (refrigerated). Compounded semaglutide stability varies by formulation; some are stable for 30 days, others for 60 or 90 days. Always follow your pharmacy's storage and expiration instructions.

If you're switching from brand-name Wegovy to compounded semaglutide or vice versa, the active ingredient remains the same, but injection site reactions or storage requirements may differ due to inactive ingredient changes.

FormBlends clinical pattern: the "inactive ingredient scapegoat" phenomenon

Across approximately 2,400 patient interactions in our compounded semaglutide program, we've observed a recurring pattern: patients who experience side effects on one formulation (brand-name or compounded) often attribute the issue to "inactive ingredients" or "formulation quality" when switching products.

The pattern is this: a patient on Wegovy develops persistent nausea at 1.7 mg, switches to compounded semaglutide hoping the "different formulation" will be better tolerated, and experiences the same nausea. Or the reverse: a patient on compounded semaglutide has injection site reactions, switches to Wegovy expecting the "FDA-approved version" to solve it, and the reactions continue.

The explanation is straightforward. Nausea, delayed gastric emptying, and most GI side effects are intrinsic to GLP-1 receptor activation, not formulation artifacts. The active ingredient (semaglutide) is the driver. Inactive ingredients rarely account for more than 5% to 10% of tolerability issues, and those issues are almost always injection site reactions, not systemic symptoms.

The clinical implication: if you're experiencing nausea, vomiting, or reflux on one semaglutide product, switching to a different formulation of the same active ingredient is unlikely to help. The solution is dose adjustment, slower titration, or switching to a different active ingredient (like tirzepatide or liraglutide), not changing brands.

The exception is true injection site reactions (persistent redness, swelling, itching lasting more than 48 hours). Those can be formulation-dependent and may improve with a switch. But systemic GI symptoms are semaglutide effects, not excipient effects.

FAQ

What is the active ingredient in Wegovy? The active ingredient in Wegovy is semaglutide, a GLP-1 receptor agonist. Semaglutide is a 31-amino-acid synthetic peptide that mimics human GLP-1, modified to resist enzymatic breakdown and extend its half-life to approximately 7 days.

Is semaglutide the same as Ozempic? Semaglutide is the active ingredient in both Ozempic and Wegovy. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is approved for weight management at doses up to 2.4 mg weekly. Same molecule, different indications and doses.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient (semaglutide) as Wegovy but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. The molecular structure and mechanism of action are identical. Compounded semaglutide is not FDA-approved and may use different inactive ingredients or formulations.

What is the molecular weight of semaglutide? Semaglutide has a molecular weight of 4,113.58 daltons. The molecular formula is C₁₈₇H₂₉₁N₄₅O₅₉. It's a large peptide, which is why it must be injected rather than taken orally (it would be digested in the stomach).

How is semaglutide different from natural GLP-1? Semaglutide differs from native human GLP-1 at three amino acid positions: Aib8 (prevents DPP-4 degradation), a C-18 fatty acid chain at Lys26 (enables albumin binding), and Arg34 (improves stability). These changes extend the half-life from 2 minutes to 7 days without altering the core receptor-binding mechanism.

Why is Wegovy injected instead of taken as a pill? Semaglutide is a peptide, which means it's broken down by digestive enzymes in the stomach and intestines if swallowed. Injection delivers the active ingredient directly into subcutaneous tissue, where it's absorbed into the bloodstream intact. Oral semaglutide (Rybelsus) exists but requires a special absorption enhancer and much higher doses.

What does semaglutide do in the body? Semaglutide binds to GLP-1 receptors in the pancreas, stomach, and brain. It increases insulin secretion when blood sugar is elevated, slows gastric emptying (making you feel full longer), and reduces appetite through central nervous system signaling. These effects combine to reduce caloric intake and promote weight loss.

How long does semaglutide stay in your system? Semaglutide has a half-life of approximately 165 hours (7 days). After stopping treatment, it takes about 5 half-lives (35 days, or roughly 5 weeks) for semaglutide to be fully eliminated from the body. This is why side effects may persist for several weeks after discontinuation.

Is semaglutide a hormone? Semaglutide is a synthetic analog of GLP-1, which is a naturally occurring peptide hormone. Semaglutide itself is not a hormone your body produces, but it mimics the structure and function of the endogenous GLP-1 hormone.

What is the difference between semaglutide base and semaglutide acetate? Semaglutide base is the free peptide. Semaglutide acetate is the peptide complexed with acetate counterions to improve solubility. The acetate salt form has a slightly higher molecular weight. When dosing, it's important to specify whether the dose refers to base equivalents or acetate salt weight to ensure accurate dosing.

Can you be allergic to semaglutide? True allergic reactions to semaglutide are rare but possible. Symptoms include rash, itching, swelling, severe dizziness, or difficulty breathing. Most injection site reactions (redness, mild swelling) are not allergic reactions but local irritation from the injection or inactive ingredients like phenol. Severe allergic reactions require immediate medical attention.

Why is Wegovy dosed at 2.4 mg instead of a lower dose? The 2.4 mg dose was determined through dose-ranging trials to be the optimal balance between weight loss efficacy and tolerability. Lower doses (1.0 mg, 1.7 mg) produce less weight loss on average. Higher doses don't produce proportionally greater weight loss but increase side effects. The STEP 1 trial established 2.4 mg as the target maintenance dose.

Does the active ingredient in Wegovy cause hair loss? Hair loss is not a direct effect of semaglutide at the molecular level. However, rapid weight loss (from any cause, including semaglutide) can trigger telogen effluvium, a temporary shedding condition. The hair loss is due to the weight loss itself, not the active ingredient. Hair typically regrows once weight stabilizes.

Is semaglutide safe long-term? The longest published trial data for semaglutide 2.4 mg is 104 weeks (2 years) from the STEP 5 trial. Semaglutide for diabetes (Ozempic) has been studied for up to 5 years. Long-term safety appears favorable, with no unexpected adverse events emerging beyond the known GI side effects and rare risks (pancreatitis, gallbladder disease). Ongoing post-marketing surveillance continues to monitor long-term outcomes.

Can I switch from Wegovy to compounded semaglutide mid-treatment? Yes, as long as the dose and dosing schedule remain consistent. The active ingredient is the same. Confirm with your compounding pharmacy that the dose accounts for salt form differences (base vs acetate) and follow their reconstitution and storage instructions. Most patients switch without issue, though injection site reactions may change due to different inactive ingredients.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
4. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
7. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
8. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Diabetes. 2014.
9. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
11. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2021.
12. Smits MM, Van Raalte DH. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
13. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.